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Characterisation of the PAM binding site 
 
Subversion of the plasminogen activation 
system is implicated in the virulence of 
group A streptococci (GAS). GAS display 
receptors for the human zymogen 
plasminogen on the cell surface, one of 
which is the plasminogen-binding group A 
streptococcal M-like protein (PAM). The 
plasminogen binding domain of PAM is 
highly variable, and this variation has been 
linked to host selective immune pressure. 
Site-directed mutagenesis of full length 
PAM protein from an invasive GAS isolate 
was undertaken to assess the contribution 
of residues in the a1 and a2 repeat domains 
to plasminogen binding function. 
Mutagenesis to alanine of key plasminogen 
binding lysine residues in the a1 and a2 
repeats (Lys98 and Lys111) did not abrogate 
plasminogen binding by PAM, nor did 
additional mutagenesis of Arg101 and His102 
and Glu104, which have previously been 
implicated in plasminogen binding. 
Plasminogen binding was only abolished 
with the additional mutagenesis of Arg114 
and His115 to alanine. Furthermore, 
mutagenesis of both arginine (Arg101 and 
Arg114) and histidine (His102 and His115) 
residues abolished interaction with 
plasminogen despite the presence of Lys98 
and Lys111 in the binding repeats. This 
study shows for the first time that residues 
Arg101, Arg114, His102 and His115 in both the 
a1 and a2 repeat domains of PAM can 
mediate high affinity plasminogen binding. 
These data suggest that highly conserved 
arginine and histidine residues may 
compensate for variation elsewhere in the 
a1 and a2 plasminogen binding repeats, and 
may explain the maintenance of high 
affinity plasminogen binding by naturally 
occurring variants of PAM. 
 
The Gram positive bacterium Streptococcus 
pyogenes (group A streptococcus, GAS)1 is 
responsible for a wide variety of skin and 
mucosal infections in humans. Current 
estimates indicate that approximately 1.78 
million new cases of severe streptococcal 
infection occur each year (1). A key feature of 
invasive GAS infections is the ability of the 
organism to migrate from cutaneous and 
mucosal surfaces to deep tissue sites, resulting 
in severe invasive disease. The binding and 
activation of plasminogen by GAS has been 
implicated in the pathogenesis of this 
organism (2).  
 
Plasminogen is a single chain glycoprotein 
found in plasma and extracellular fluids at 
concentrations of approximately 2 μM (3). 
Cleavage of plasminogen at a single site 
(Arg560-Val561) by specific plasminogen 
activators results in the formation of the two-
chain plasmin molecule, which contains a 
serine protease active site in the C-terminal 
region (4). Human plasminogen can also be 
activated to plasmin by the GAS protein 
streptokinase, as part of a highly species 
specific plasminogen/streptokinase activator 
complex (2). Plasmin has the ability to 
degrade fibrin clots, connective tissue and the 
extracellular matrix (3,4). Thus activation of 
this proteolytic system by GAS may have 
significant pathological consequences in the 
host (5).  
 
Isolated initially from M53 serotype GAS, the 
plasminogen-binding group A streptococcal 
M-like protein (PAM) is a 42 kDa molecule 
which binds both plasmin and plasminogen 
directly and with high affinity (Kd ~ 1 nM) (6). 
A newly developed model of GAS infection 
using mice expressing a human plasminogen 
transgene indicates that plasminogen plays a 
critical role in GAS infection, with a 
significant increase in mortality observed in 
transgenic mice when compared to wild type 
littermate control mice (5). Additionally, the 
PAM-positive GAS isolate AP53 exhibited a 
60% increase in mortality in transgenic mice 
when compared to wild type littermates, and a 
PAM negative isogenic mutant of this strain 
showed only minimal virulence in both wild 
type and human plasminogen transgenic 
murine backgrounds (5). Thus, it appears that 
for a subset of GAS isolates, the ability of 
PAM to focus plasminogen at the GAS cell 
surface is crucial for virulence.  
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The major plasmin(ogen)-binding site of PAM 
is located in the N-terminal variable region of 
the protein, and is comprised of two 
characteristic tandem repeats designated a1 
and a2. Similar binding motifs have been 
identified in M-like proteins of other GAS 
isolates associated with skin infection (6,7). 
PAM has been implicated in the establishment 
of GAS skin infections such as impetigo, and 
the PAM genotype is almost exclusively 
associated with the chromosomal emm pattern 
D, which is considered a genetic marker for 
skin tropic GAS (7-9). However, in the 
Northern Territory of Australia, where 
streptococcal skin infection is endemic and 
high rates of invasive infection such as 
bacteraemia have been reported (10), PAM 
positive GAS are associated with a variety of 
disease states (11). The plasminogen binding 
domain of PAM has been shown to be highly 
variable, however, this diversity does not 
abrogate plasminogen binding by naturally 
occurring PAM variants (12). This finding 
may, in part, be due to the conservation of key 
amino acid residues within the plasminogen 
binding domain (11,12). Plasmin(ogen) is 
known to interact with its ligands via pre-
formed lysine binding-sites within the N-
terminally located triple-disulfide bonded 
kringle domains (4). Kringles 1, 4 and 5 
display the highest affinity for lysine-based 
ligands, with kringle 2 displaying the weakest 
affinity (13). PAM lacks the typical C-
terminal lysine residues characteristic of many 
plasminogen receptors. Rather, internal lysine 
residues in the a1 and a2 repeat regions of 
PAM (Lys98 and Lys111) are thought to 
mediate binding to kringle 2 of plasminogen 
(14). Early reports suggested that Lys98 of the 
a1 repeat contributed the majority of the 
plasminogen binding ability of PAM (14). 
However, studies involving a polypeptide 
designated VEK-30 and a recombinant kringle 
2 modified to contain a high affinity lysine 
binding site, highlighted a potential role for 
internal His102, Arg101 and Glu104 residues 
within the a1 repeat in this interaction (15,16). 
VEK-30 is comprised of the six residues 
preceding the a1 repeat, the entire a1 repeat, 
together with the first ten residues of the a2 
repeat of PAM (17). The relative contribution 
to binding by residues within the a1 and a2 
repeat of the full length PAM protein to 
plasminogen has not been characterised.  
 
Here, we have undertaken site-directed 
mutagenesis studies on the PAM molecule and 
defined residues involved in the interaction 
with plasminogen. These studies highlight the 
important contribution of multiple arginine 
and histidine residues within both the a1 and 
a2 plasminogen binding domains and may 
explain the capacity of naturally occurring 
PAM variants to maintain high affinity 
plasminogen binding despite considerable 
variation observed in the plasminogen binding 
repeats.  
  
MATERIALS AND METHODS 
Bacterial strains and culture methods - 
Escherichia coli TOP10 containing pGEX2T-
PAMNS13 expression plasmids were grown on 
Luria Bertani (LB) agar plates or cultured in 
LB broth supplemented with ampicillin (100 
μg/ml) as described previously (18). Plasmid 
DNA was extracted for PCR and DNA 
sequence analysis using the Wizard ® Plus SV 
DNA purification kit (Promega, USA).   
 
Site-directed mutagenesis - The PAM gene 
from streptococcal strain NS13 (PAMNS13 
GenBank™ AY351851), which is identical to 
the prototype PAM sequence in the a1 and a2 
repeat domain, had previously been cloned 
into the expression vector pGEX2T (12). To 
assess the role of specific binding-site residues 
in the interaction of PAM with plasminogen, 
site-specific mutations were introduced into 
the PAMNS13 binding site. The wild type 
construct (100 ng) was used as template DNA 
to create site-directed mutants with the 
QuickChange™ site-directed mutagenesis kit 
(Stratagene, USA). PCR reactions consisted of 
1x Pfu reaction buffer (Stratagene, USA), 
0.25mM dNTPs (Boehringer Mannheim, 
Germany), 2.5 U of Pfu Ultra polymerase 
(Stratagene, USA), and 125 ng of each primer, 
made up to a volume of 50 μl with dH2O. 
Oligonucleotide Primers (Sigma-Aldrich) 
were designed as per the manufacturers 
instructions (Stratagene, USA). In general, 
primers consisted of sequence encoding the 
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desired mutation, flanked on either side by 
fifteen nucleotides of wild type sequence. The 
specific primer sequences are given in Table 
1, with the introduced mutations underlined. 
For site-directed mutants containing more than 
two mutations not encoded by a single primer, 
alanine residues were sequentially introduced 
using previously mutated DNA as a template. 
Following an initial denaturation step (95°C, 
30 sec), PCR cycling parameters consisted of 
sixteen cycles of 95°C for 30 sec, 55°C for 1 
min and 68°C for 10 min. An additional 7 min 
extension at 55°C was then performed. PCR 
was conducted with a Cooled Palm 96 
thermocycler (Corbett Research). Non-
amplified template DNA was removed by 
incubation of reactions for 1 h at 37°C 
following the addition of Dpn I (10 U/ 50 μl 
reaction). E. coli TOP10 (Invitrogen, USA) 
were transformed with 150 ng of Dpn I 
digested PCR product using standard 
procedures (18).  
 
DNA sequence analysis, expression and 
purification of recombinant M proteins - DNA 
sequence analysis was used to verify 
introduced mutations and confirm the absence 
of random mutations in site-directed mutants. 
DNA sequence analysis was performed using 
the primers listed in Table 1, and sequence 
reactions undertaken using terminator ready 
reaction mix (PE Applied Biosystems, USA). 
DNA sequencing gels were prepared as per the 
manufacturers instructions and 
electrophoresed using an Applied Biosystems 
3130 X Genetic Analyser (Applied 
Biosystems, USA). Sequence data was 
analysed using ABI Prism™ DNA sequencing 
analysis software (Perkin Elmer, USA).  
 
Recombinant proteins were expressed and 
purified essentially as described previously 
(12,19), from 1 L E. coli cultures, using 
glutathione agarose (Sigma-Aldrich, USA) 
and native Ni-NTA agarose (Qiagen, 
Germany) affinity chromatography. Prior to 
elution from the glutathione agarose column, 
the GST tag was removed from the N-
terminus of recombinant fusion proteins by the 
addition of one column volume of thrombin 
solution (1 U thrombin/μl, PBS pH 8.0). The 
column was incubated for 5 h at room 
temperature and the cleaved recombinant 
protein eluted in PBS (pH 8.0). Each step of 
the protein purification process was monitored 
by 12% SDS-polyacrylamide gel 
electrophoresis (PAGE) analysis (20), with 
protein visualised using Coomassie R 250 
staining.  
 
Circular dichroism spectroscopy - To examine 
potential variation in protein secondary 
structure as a result of site-directed 
mutagenesis, far UV Circular dichroism (CD) 
spectra were obtained for both wild type and 
mutant recombinant PAM proteins. CD 
spectra were acquired using a Jasco J-810 
Spectropolarimeter (Jasco, Canada) at room 
temperature. CD spectra data was recorded 
from 190 – 250 nm in a 1 cm pathlength cell 
containing 1.5 ml of protein solution at a 
concentration of 0.04 mg/ml in 10 mM sodium 
phosphate buffer (pH 7.4). Recorded data 
represents the average of six scans, corrected 
for buffer baseline. Molar residue ellipticity 
([θ]) was calculated using the following 
formula:  
[θ] = θ × 100 × Molecular weight / 
concentration (mg/ml) × distance × Number of 
amino acids (21) .  
The percentage of α-helix was estimated from 
the ellipticity at 222 nm using the following 
formula: % α-helix = - (θ222 nm – 4,800)/45,400 
(22). 
 
Plasminogen purification and labeling - Glu-
plasminogen was purified from human plasma 
using lysine Sepharose-4B affinity 
chromatography as described previously 
(12,23). Purified plasminogen was 
biotinylated by the addition of 10% (v/v) 1 M 
NaHCO3 (pH 9), and a 40 molar excess of 
biotin-X-NHS in dimethyl sulfoxide (Sigma-
Aldrich, USA). The reaction was incubated at 
4°C overnight with mixing. Free biotin was 
separated from biotinylated plasminogen by 
PD-10 gel filtration chromatography 
(Amersham Biosciences, USA) (12). 
 
Plasminogen binding analysis - Solid phase 
plasminogen binding assays were performed 
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in order to assess the impact of introduced 
mutations on protein function essentially as 
previously described (12). Ninety-six well 
microtitre plates (Greiner Bio-one, Germany) 
were coated with 150 nM recombinant protein 
(50 μl in 0.1 M NaHCO3) at 4°C overnight. 
Following three washes with PiNT (50 mM 
Na2HPO4, 150 mM NaCl, 0.05% Tween-80, 
pH 7.5), plates were blocked with 50 μl of 
blocking solution (1% skim milk powder, 
PiNT) for 1 h at 37°C.  Wells were washed as 
above, and 500 nM biotinylated glu-
plasminogen was diluted in a three-fold 
titration across the plate with blocking buffer, 
in the presence or absence of a 50 fold molar 
excess of unlabelled glu-plasminogen. 
Plasminogen was allowed to bind to 
immobilised proteins for 2 h at room 
temperature. For competition assays, 
decreasing concentrations of unlabelled fluid 
phase wild type PAMNS13 (25 μM-0.14 nM) 
were allowed to compete with immobilised 
proteins for binding to biotinylated glu-
plasminogen. Competitor was titrated three-
fold across the microtitre plate prior to the 
addition of biotinylated glu-plasminogen to all 
wells, at a final concentration of 500 nM. The 
assay was incubated for 2 h at room 
temperature. Following the plasminogen 
incubation step, microtitre plates were washed 
three times, and 50 μl of neutravidin 
conjugated to horse radish peroxidase (Progen, 
Australia) diluted 1:5000 with blocking 
solution was added to all wells and incubated 
for 2 h at room temperature. After five washes 
with PiNT, the reactions were developed by 
the addition of 50 μl o-phenylenediamine 
(Sigma-Aldrich, USA) substrate (8 mM 
Na2HPO4 pH5.0, 2.2mM o-phenylenediamine, 
3% H2O2). Colour development was stopped 
by the addition of 50 μl of 10 M hydrochloric 
acid, and the plates were read at 490 nm using 
a Spectramax 250 plate reader (Molecular 
Devices, USA).  
 
Data was normalised against the highest and 
lowest absorbance value for each assay, and 
non-linear regression analysis performed using 
GraphPad® Prism (v4.00, GraphPad software, 
CA). For the calculation of equilibrium 
binding dissociation constants (Kd), a one 
versus two site binding analysis was 
conducted and the best-fit curve fitted to the 
data. For competition experiments, a one-site 
competition curve was fitted to the data from 
which the effective concentration of 
competitor required to inhibit binding by 50% 
(EC50) was calculated.  
 
Statistical analysis - For plasminogen binding 
experiments, a one-way ANOVA was initially 
used on all data, followed by an unpaired t-test 
with Welsch’s correction to determine if there 
was any significant difference in the Kd values 
for plasminogen binding by PAM mutants and 
PAMNS13. 
 
RESULTS 
The gene encoding wild type PAMNS13 shares 
100% identity with the prototype PAM 
sequence in the a1 and a2 repeat domain 
responsible for the interaction with 
plasminogen (11). In order to assess the role of 
specific binding site residues in the interaction 
of PAMNS13 with plasminogen, a number of 
site-directed mutants were constructed in 
which the residues of interest were replaced 
with alanine. The binding site sequences of the 
five constructed mutants are shown in Fig. 1A. 
The presence of introduced mutations was 
verified by DNA sequence analysis. Following 
expression in E. coli, recombinant proteins of 
approximately 40 kDa in size were purified 
using glutathione-agarose and Ni-NTA 
agarose affinity chromatography (Fig. 1B).  
 
The impact of mutations in the a1 and a2 
repeat domains of PAMNS13 on protein 
structure were analysed using far UV CD 
spectroscopy. All proteins used in this study 
were found to have a CD emission spectrum 
characteristic of α-helical coiled proteins (24), 
displaying two characteristic minima at 
approximately 210 nm and 220 nm, and a 
maximum peak at 190 nm (Fig. 2). This is 
similar to the CD spectra of other 
streptococcal M proteins, which are coiled-
coil α-helical proteins (22). Thus, even after 
mutagenesis these proteins appear to maintain 
an α-helical secondary structure. Additionally, 
for all proteins the two minima are of a similar 
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magnitude, which is indicative of coiled-coil 
proteins (25). Percent  α-helicity ranged from 
27% to 44% (Table 2). CD analysis of other 
streptococcal M proteins has found them to 
contain between 23% and 70% α-helix 
(22,26). 
 
PAMNS13 has previously been shown to 
interact with glu-plasminogen with high 
affinity (Kd ~ 1 nM) (12). To determine the 
impact of the introduced mutations in the 
PAMNS13 binding site on plasminogen binding, 
solid phase binding assays were performed 
utilising biotinylated glu-plasminogen. The 
recombinant PAM mutants bound 
plasminogen in a dose-dependant fashion, and 
saturable binding was achieved with 500 nM 
plasminogen for 3 of the 5 mutant proteins 
after 2 h (Fig. 3). Non-linear regression 
analysis was used to determine the affinity of 
each recombinant protein for glu-plasminogen 
(Table 2). Equilibrium dissociation constants 
(Kd) were calculated using a best-fit non-linear 
regression curve. The following site-directed 
mutants where residues were replaced with 
alanine, PAMNS13[K98 K111] and PAMNS13[K98 
R101 H102 E104 K111], bound plasminogen with 
Kd values of 10.34 nM and 50.24 nM 
respectively. Whilst this represents a 
significant decrease in affinity for glu-
plasminogen when compared to wild type 
PAMNS13 ( Kd = 1.58 nM; p < 0.05), binding 
by these mutants was still specific and 
saturable. PAMNS13[R101 H102] bound 
plasminogen with a Kd value of 1.69 nM, 
which is not significantly different from that 
of wild type PAMNS13 (p > 0.05). Only non-
specific plasminogen binding was seen for 
mutants PAMNS13[K98 R101 H102 E104 K111 R114 
H115] and PAMNS13[R101 H102 R114 H115], 
indicating that the arginine and histidine 
residues in both repeat domains are critical 
residues in the interaction of PAM with 
plasminogen.  
 
To further explore the contribution of these 
residues to the interaction with plasminogen, 
competition binding experiments were 
performed. The effective concentration of 
competitor required to inhibit plasminogen 
binding by 50% (EC50) was determined by 
fitting a one-site competition curve (Fig. 4). 
EC50 values ranged from 0.25 μM to 22.06 
μM. This represents a greater than 90% 
decrease in EC50 values for mutant proteins 
PAMNS13[K98 K111], PAMNS13[K98 R101 H102 
E104 K111] and PAMNS13[R101 H102], when 
compared to wild type PAMNS13. As expected, 
there was an inverse correlation between Kd 
and EC50 (Table 2). These data indicate that 
whilst mutation of residues Lys98, Arg101, 
His102, Glu104 and Lys111 within the 
plasminogen binding repeats of PAMNS13 
decreases the avidity of the interaction with 
plasminogen, the simultaneous mutation of 
residues Arg101, His102, Arg114 and His115 is 
required to fully abolish binding.  
 
DISCUSSION 
A key feature of certain strains of S. pyogenes 
is the ability to migrate from cutaneous and 
mucosal surfaces to deep tissue sites, resulting 
in serious invasive infections such as 
bacteraemia, necrotising fasciitis and 
streptococcal toxic shock-like syndrome. The 
exact mechanisms of GAS invasive infection 
have yet to be fully explained, however one 
hypothesis involves the interaction of GAS 
with the host plasminogen activation system. 
Four GAS plasminogen binding proteins have 
been described in the literature, as well as the 
secreted plasminogen activator streptokinase 
(2,27-29). The multiplicity of potential 
virulence factors associated with S. pyogenes 
that interact with the plasminogen activation 
system necessitates a deeper understanding of 
the relationship of GAS with plasminogen.  
 
PAM is a cell surface exposed, high affinity 
plasminogen receptor expressed by GAS 
associated with a variety of disease states, and 
appears to play an integral role in the 
plasminogen-dependant virulence of PAM 
positive GAS. In a recent study, it was shown 
that elimination of PAM dependant 
plasminogen binding by GAS significantly 
reduced mortality in mice expressing the 
human plasminogen transgene (5). 
Furthermore, whilst the plasminogen binding 
domain of PAM is highly variable, this 
variation does not appear to significantly 
impact on the high affinity interaction of PAM 
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with plasminogen. The conservation of 
binding function in spite of sequence diversity 
is indicative of the physiological significance 
of this interaction, and the ability of GAS to 
subvert the host plasminogen activation 
system (12).  
 
The a1 and a2 repeat domains in the N-
terminus of PAM mediate binding to kringle 2 
of plasminogen, with the a1 repeat residue 
Lys98 generally considered to make the 
greatest contribution to this interaction 
(6,14,17). Using site-directed mutagenesis, 
this study indicates that residues Arg101 and 
His102 within the a1 repeat, together with 
residues Arg114 and His115 within the a2 repeat, 
are critical for the interaction of full length 
PAM with plasminogen. The interaction with 
plasminogen of site-directed mutant 
PAMNS13[K98 K111] in which residues Lys98 
and Lys111 were mutated to alanines was dose-
dependant and specific. Additionally, the Kd 
value for this interaction was within a 
physiologically relevant concentration of 
plasminogen, which circulates in the 
bloodstream at a concentration of 
approximately 2 μM (3). Furthermore, 
mutation of binding site residues Arg101, 
His102, Arg114 and His115 abolished 
plasminogen binding by PAMNS13 despite the 
presence of residues Lys98 and Lys111. To our 
knowledge, this is the first demonstration of a 
non-lysine-dependent, high affinity interaction 
between plasminogen and a full-length 
naturally occurring receptor. 
 
Previous studies involving the interaction of a 
polypeptide sequence designated VEK-30 
with modified kringle 2 of plasminogen 
highlighted the importance of PAM a1/a2 
residues Lys98, Arg101, His102, Glu104 and 
Lys111 in the peptide/plasminogen interaction 
(15,16). Notably, VEK-30 lacks the final three 
residues of the a2 repeat (Arg114, His115, 
Glu116). Mutation of residues Lys98, Arg101, 
His102, Glu104 and Lys111 in the full-length 
protein PAMNS13 in this study did not eliminate 
plasminogen binding. However, the avidity of 
this interaction was significantly reduced, as 
evidenced by a greater than 90% decrease in 
EC50 values recorded for mutant proteins when 
compared to wild type PAMNS13. This supports 
the previous finding that these residues are 
important in the interaction of PAM with 
plasminogen. However, the finding that 
mutation of arginine (Arg101 and Arg114) and 
histidine (His102 and His115) residues in both 
the a1 and a2 repeat was required to fully 
abrogate plasminogen binding suggests that 
both repeats are able to mediate high affinity 
interactions with plasminogen. Residues 
Arg101 and His102 of the a1 repeat of PAM 
have been shown to make numerous saltbridge 
and hydrophobic electrostatic interactions with 
recombinant kringle 2, forming a pseudo-
ligand similar to the lysine analogue ε- amino 
caproic acid (16). It is thus likely that the 
corresponding residues Arg114 and His115 in the 
a2 repeat interact with plasminogen in a 
similar fashion. 
 
The decrease in plasminogen binding by site-
directed mutants reported here does not appear 
to be due to loss of secondary structure, as all 
site-directed mutants displayed CD spectra 
characteristic of coiled-coil alpha-helical 
proteins, similar to that of the wild type 
PAMNS13. The percent α-helicity for mutants 
reported here was between 27% and 44%. CD 
analysis of other streptococcal M proteins has 
found them to contain between 23% and 70% 
α-helix (22, 26). However, the spectra for all 
α-helical proteins are not identical due to the 
small effect of non-aromatic side chains on the 
rotary strength of the peptide bond, and 
occasional helix distortions (24). It has also 
been shown that the α-helical structure of the 
peptide VEK-30, representative of the a1 
repeat of PAM, increases from 25% to 75% 
upon binding to kringle 2 of plasminogen (16). 
It is possible that a similar structural shift 
could occur in the full length PAM protein. No 
correlation was seen between percent α-
helicity and plasminogen binding function, 
suggesting that any secondary structure 
changes have had only a minor influence on 
the differences in plasminogen binding 
described here.  
 
We have recently shown that whilst the 
plasminogen binding domain of PAM is 
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Recent findings that the acquisition of 
plasminogen by S. pyogenes may be crucial 
for the virulence of certain strains of GAS, and 
the ability of multiple GAS proteins to 
facilitate this process, necessitates a deeper 
understanding of the mechanisms via which 
certain GAS proteins interact with 
plasminogen. This study highlights for the first 
time the importance of highly conserved 
arginine (Arg101 and Arg114) and histidine 
(His102 and His115) residues within the binding 
site of the plasminogen binding protein PAM, 
in mediating the interaction of this molecule 
with plasminogen. Such a finding may have 
implications for the identification of novel 
plasminogen binding proteins in the future.  
highly variable, this diversity does not 
abrogate plasminogen binding by naturally 
occurring PAM variants (12). In these 
naturally occurring PAM variants, the Arg and 
His residues in both a1 and a2 repeat domains 
are highly conserved (11). Interestingly, in this 
study, a loss of plasminogen binding was only 
observed following simultaneous mutation of 
both the Arg101 and His102 residues in the a1 
repeat, and the Arg114 and His115 residues in 
the a2 repeat. Therefore, conservation of Arg 
and His residues in either repeat domain may 
compensate for variation elsewhere in the 
binding repeats, and explain the maintenance 
of high affinity plasminogen binding by 
naturally occurring variants of PAM. 
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Table 1. Forward primers used for PCR construction and DNA sequence analysis of 
PAMNS13 site directed mutants. Underlined sequences indicate introduced mutations. For 
site-directed mutants containing two or more mutations not encoded in a single primer, 
mutations were sequentially introduced using previously mutated DNA as a template. 
 
Introduced 
Mutation 
Forward Mutagenesis Primer 
K98/A 
K111/A 
R101H102E104/A 
R101H102/A 
R114H115/A 
5’-GATGCTGAGTTGCAACGACTTGCAAACGAGAGACATGAAGAAGCA-3’ 
5’-GAAGCAGAGTTGGAGCGACTTGCAAGCGAGAGACATGATCATGAC-3’ 
5’-CGACTTGCAAACGAGGCAGCAGAAGCAGCAGAGTTGGAGCGA-3’ 
5’-CGACTTGCAAACGAGGCAGCAGAAGCAGCAGAGTTGGAGCGA-3’ 
5’-CGACTTGCAAGCGAGGCAGCAGATCATGACAAAAAAGAAGC-3’ 
 
Primer DNA Sequence Analysis Primers 
PAMF1 
PAMR1 
PAMF2 
PAMR2 
PAMF3 
PAMR3 
pGEX2TF 
pGEX2TR 
5’-ATAAGCAAGAACATCTTGACGG-3’ 
5’-CTGTTAATTTCTTGCTTTC-3’ 
5’-AAAGGGCTTAAGACTGATTTAC-3’ 
5’-GACCAGCTAATTTGCTGTTTGC-3’ 
5’-GCAAACAGCAAATTAGCTGCTC-3’ 
5’-CTTCTCAACATCATCTTTAAGG-3’ 
5’-GGGCTGGCAAGCCACGTTTGGTG-3’ 
5’-CCGGGAGCTGCATGTGTCAGAGG-3’ 
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Table 2. Functional and structural characteristics of PAMNS13 site –directed mutants. 
 
Protein Kd (nM) EC50 (μM) % α - 
helix 
PAMNS13
PAMNS13[K98K11] 
PAMNS13[K98R101H102E104K111] 
PAMNS13[K98R101H102E104K111R114H115] 
PAMNS13[R101H102]  
PAMNS13[R101H102R114H115] 
1.58 
10.34 
50.24 
Non-specific binding only 
1.69 
Non-specific binding only 
22.06 
0.57 
0.25 
Not determined 
4.87 
Not determined 
27 
41 
33 
44 
33 
29 
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Fig 1. A Alignment of the plasminogen binding domain of wild type PAMNS13 with the 5 
site-directed mutants constructed in this study. Mutated residues are indicated in bold. B 
12% SDS-PAGE gel showing the 6 purified recombinant proteins used in this study. 
Lane 1, PAMNS13 ; lane 2, PAMNS13[K98 K111]; lane 3 PAMNS13[K98 R101 H102 E104 K111]; 
lane 4, PAMNS13[K98 R101 H102 E104 K111 R114 H115]; lane 5, PAMNS13[R101 H102]; lane 6, 
PAMNS13[R101 H102 R114 H115]. Molecular weight markers are given in kilo Daltons (kDa). 
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Fig 2. Circular dichroism spectra of recombinant PAMNS13 mutants. A PAMNS13; B 
PAMNS13[K98 K111]; C PAMNS13[K98 R101 H102 E104 K111]; D PAMNS13[K98 R101 H102 E104 
K111 R114 H115]; E PAMNS13[R101 H102]; F PAMNS13[R101 H102 R114 H115] All proteins 
exhibit CD emission spectrum characteristic of α-helical coiled proteins (24), displaying 
two characteristic minima at approximately 210 nm and 220 nm, and a maximum peak at 
190 nm 
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Fig 3. Saturation binding analysis of biotinylated glu-plasminogen to immobilised 
recombinant PAMNS13 mutant proteins. Biotinylated glu-plasminogen binding to 
immobilised recombinant protein (A PAMNS13; B PAMNS13[K98 K111]; C PAMNS13[K98 
R101 H102 E104 K111]; D PAMNS13[K98 R101 H102 E104 K111 R114 H115]; E PAMNS13[R101 H102]; 
F PAMNS13[R101 H102 R114 H115] ) was measured in the absence (▼, total binding) and 
presence (●, non-specific binding) of a 50 fold molar excess of unlabelled glu-
plasminogen. Specific binding (■) was determined by subtracting non-specific binding 
from total binding at each concentration. A one-site hyperbolic binding function was 
fitted to the data (p < 0.05), from which the binding dissociation constants were 
determined. Error bars represent the standard error of the mean (SEM; n = 3).  
 15
Characterisation of the PAM binding site 
 
 
Fig 4. Competition of glu-plasminogen binding to immobilised recombinant PAM 
variants with fluid phase PAMNS13. Binding of biotinylated glu-plasminogen to 
immobilised A PAMNS13, B PAMNS13[K98 K111]; C PAMNS13[K98 R101 H102 E104 K111], and 
D PAMNS13[R101 H102] was measured in the presence of varying concentrations of 
unlabelled fluid phase PAMNS13. Data points are the mean values of triplicate readings, 
with error bars indicating the standard error of the mean (SEM; n=3). One-site 
competition analysis was performed on data for all recombinant proteins; this analysis 
was used to determine the concentration of PAMNS13 required to inhibit binding of 
biotinylated glu-plasminogen by 50% (EC50). 
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